Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related

Disease Markers

Volumn 25, Issue 1, 2008, Pages 37-47

  Cardoso, I ^a   Brito, M ^a   Saraiva, M J ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Biglycan; Extracellular matrix; Familial amyloid polyneuropathy; Metalloproteinase 9; Neutrophil gelatinase associated lipocalin; Transthyretin

Indexed keywords

AMYLOID; BIGLYCAN; CHONDROITIN SULFATE; CONGO RED; DOXYCYCLINE; GELATINASE B; MUTANT PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PREALBUMIN; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FAMILIAL AMYLOID POLYNEUROPATHY; FIBER; FOLLOW UP; GLYCATION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 50249169221     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/549872     Document Type: Article

References (33)

1. C.R. Abraham, D.J. Selkoe and H. Potter, Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell 52 (1988), 487-501.
2. M.R. Almeida, A.M. Damas, M.C. Lans, A. Brower and M.J. Saraiva, Thyroxine binding to transthyretin Met119. Comparative studies of different heterozygotic carriers and structural analysis, Endocrine 6 (1997), 309-315.
3. A.I. Bush, W.H. Pettingell, G. Multhaup, M. d Paradis, J.P. Vonsattel, J.F. Gusella, K. Beyreuther, C.L. Masters and R.E. Tanzi, Rapid induction of Alzheimer A beta amyloid formation by zinc, Science 265 (1994), 1464-1467.
4. I. Cardoso and M.J. Saraiva, Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model, FASEB J 20 (2006), 234-239.
5. I. Cardoso, G. Merlini and M.J. Saraiva, 4′-iodo-4′- Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing non- cytotoxic species. Screening for TTR fibril disrupters, FASEB J 17 (2003), 803-809.
6. I. Cardoso, C.S. Goldsbury, S.A. Müller, V. Olivieri, S. Wirtz, A.M. Damas, U. Aebi and M.J. Saraiva, Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for in vitro assembled transthyretin amyloid-like fibrils, J Mol Biol 317 (2002), 687-699.
7. N.H. Choi-Miura, Y. Ihara, K. Fukuchi, M. Takeda, Y. Nakano, T. Tobe and M. Tomita, SP-40,40 is a constituent of Alzheimer's amyloid, Acta Neuropathol (Berl) 83 (1992), 260-264.
8. A. Coimbra and C. Andrade, Familial amyloid polyneuropathy: an electron microscope study of peripheral nerve in five cases. I. Interstitial changes, Brain 94 (1971), 199-206.
9. H. Furuya, M.J.M. Saraiva, M.A. Gawinowicz, I.L. Alves, P.P. Costa, H. Sasaki, I. Goto and Y. Sakaki, Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP), Biochemistry 30 (1991), 2415-2421.
10. G. Gallo, T. Wisniewski, N.H. Choi-Miura, J. Ghiso and B. Frangione, Potential role of apolipoprotein-E in fibrillogenesis, Am J Pathol 145 (1994), 526-530.
11. G.G. Glenner, Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts), N Engl J Med 302 (1980), 1283-1292.
12. M.A. Hofmann, E. Lalla, Y. Lu, M.R. Gleason, B.M. Wolf, N. Tanji, L.J. Ferran Jr., B. Kohl, V. Rao, W. Kisiel, D.M. Stern and A.M. Schmidt, Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model, J Clin Invest 107 (2001), 675-683.
13. S. Inoue, M. Kuroiwa, M.J. Saraiva, A. Guimarães and R. Kisilevsky, Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: examination with high-resolution electron microscopy, J Struct Biol 124 (1998), 1-12.
14. S. Inoue and R. Kisilevsky, Beta-amyloid fibrils of Alzheimer's disease: pathologically altered, basement membrane-associated microfibrils? Ital J Anat Embryol 106 (2001), 93-102.
15. E.A. Kelly and N.N. Jarjour, Role of matrix metalloproteinases in asthma, Curr Opin Pulm Med 9 (2003), 28-33.
16. Y.C. Lee, H.B. Lee, Y.K. Rhee and C.H. Song, The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma, Clin Exp Allergy 31 (2001), 1623-1630.
17. O.H. Lowry, N.J. Rosenbrough, A.L. Farr and J. Randall, Protein measurement with the Folin phenol reagent, J Biol Chem 193 (1951), 265-275.
18. N. Matsunaga, I. IAnan, S. Forsgren, R. Nagai, P. Rosenberg, S. Horiuchi, Y. Ando and O.L. Suhr, Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-κB activation, Acta Neuropathol 104 (2002), 441-444.
19. F.A. Monteiro, PhD thesis. Porto University, 2006.
20. M.B. Pepys, Pathogenesis, diagnosis and treatment of systemic amyloidosis, Philos Trans R Soc Lond B Biol Sci 356 (2001), 203-210; discussion 210-211. Review.
21. M.B. Pepys, Amyloidosis: some recent developments, Q J Med 252 (1988), 283-298. Review.
22. J. Rogers, N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt, P. Ward et al., Complement activation by beta-amyloid in Alzheimer disease, Proc Natl Acad Sci USA 89 (1992), 10016-10020.
23. D.L. Scott, G. Marhaug and G. Husby, Comparative studies of the high molecular weight amyloid fibril proteins and similar components from normal tissues, Clin Exp Immunol 52 (1983), 693-701.
24. A.D. Snow, J. Willmer and R. Kisilevsky, Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest 56 (1987), 120-123.
25. M.M. Sousa, J.B. do Amaral, A. Guimaraes and M.J. Saraiva, Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy, FASEB J 19 (2005), 124-126.
26. M.M. Sousa, R. Fernandes, J.A. Palha, A. Taboada, P. Vieira and M.J. Saraiva, Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin, Am J Pathol 161 (2002), 1935-1948.
27. M.M. Sousa, I. Cardoso, R. Fernandes, A. Guimaraes and M.J. Saraiva, Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates, Am J Pathol 159 (2001), 1993-2000.
28. M.M. Sousa, S. Du Yan, R. Fernandes, A. Guimaraes, D. Stern and M.J. Saraiva, Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways, J Neurosci 21 (2001), 7576-7586.
29. M.M. Sousa, S.D. Yan, D. Stern and M.J. Saraiva, Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-B) activation, Lab Invest 80 (2000), 1101-1110.
30. P.F. Teixeira, F. Cerca, S.D. Santos and M.J. Saraiva, Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy, J Biol Chem 281 (2006), 21998-22003.
31. H. Terazaki, Y. Ando, R. Fernandes, K. Yamamura, S. Maeda and M.J. Saraiva, Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with an Y78F TTR mutant, Lab Invest 86 (2006), 23-31.
32. T. Wendt, E. Harja, L. Bucciarelli, W. Qu, Y. Lu, L.L. Rong, D.G. Jenkins, G. Stein, A.M. Schmidt and S.F. Yan, RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes, Atherosclerosis 185 (2006), 70-77.
33. S.E. Wenzel, S. Balzar, M. Cundall and H.W. Chu, Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair, J Allergy Clin Immunol 111 (2003), 1345-1352.